FDA – Page 3 – Policy & Medicine

FDA Opioid REMS: ACPE Outlines Pharmacists Role in Education

FDA: Warning Letters May Double in 2010

FDA Opioid REMS Advisory Panel Focus on CME for Improving Practice

FDA Pain REMS Advisory Committee to Include Presentations on Continuing Education in the Health Professions as a Tool for Implementation

FDA Avandia Hearing Update – Committee Votes to Keep Avandia on the Market but with Restrictions

FDA Direct to Consumer Proposed Rule: Advertising Coalition’s Response

FDA Turns to CME for Risk Evaluation and Mitigation Strategy (REMS) Pain Education

FDA Proposed Rule on Falsification of Data

Research America Study: American’s Confident in FDA and Biomedical Research

FDA: Off Label May Be the Wrong Label